Skip to main content

Advertisement

Table 1 Patient and tumor characteristics for the modified intention-to-treat population

From: FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

Characteristic LET (n = 66) mean ± SD or n and % LET + ZOL (n = 65) mean ± SD or n and % Total (n = 131) mean ± SD or n and %
Age (years)    
  Mean ± SD 70.6 ± 8.3 71.1 ± 9.1 70.8 ± 8.7
  Median (range) 71.0 (54.0–89.0) 70.0 (54.0–88.0) 71.0 (54.0–89.0)
Height (cm)    
  Mean ± SD 162.3 ± 6.7 162.5 ± 7.0 162.4 ± 6.8
  Median (range) 163 (150–185) 163 (144–180) 163 (144–185)
Body weight (kg)    
  Mean ± SD 70.7 ± 12.9 71.6 ± 16.9 71.2 ± 15.0
  Median (range) 69.0 (47.0–114.0) 70.0 (41.0–150.0) 69.2 (41.0–150.0)
BMI (kg/m2)    
  Mean ± SD 26.9 ± 4.8 27.0 ± 5.8 26.9 ± 5.3
  Median (range) 26.3 (17.0–40.4) 26.2 (16.6–55.1) 26.2 (16.6–55.1)
Postmenopausal state: yes 65 (100.0) 66 (100.0) 131 (100.0)
Age group    
  < 65 years 15 (22.7) 16 (24.6) 31 (23.7)
  ≥ 65 years 51 (77.3) 49 (75.4) 100 (76.3)
Ethnicity: Caucasian 65 (100.0) 66 (100.0) 131 (100.0)
Histological type    
  Invasive ductal 44 (66.7) 48 (73.8) 92 (70.2)
  Invasive lobular 12 (18.2) 8 (12.3) 20 (15.3)
  Invasive ductal and lobular 2 (3.0) 3 (4.6) 5 (3.8)
  Other 8 (12.1) 6 (9.2) 14 (10.7)
Grading    
  G1 10 (15.2) 10 (15.4) 20 (15.3)
  G2 47 (71.2) 46 (70.8) 93 (71.0)
  G3 9 (13.6) 8 (12.3) 17 (13.0)
  GX 0 (0.0) 1 (1.5) 1 (0.8)
T staging    
  T in situ 1 (1.5) 0 (0.0) 1 (0.8)
  T1 6 (9.1) 5 (7.9) 11 (8.5)
  T2 48 (72.7) 40 (63.5) 88 (68.2)
  T3 8 (12.1) 8 (12.7) 16 (12.4)
  T4 3 (4.5) 10 (15.9) 13 (10.1)
  Data lacking 0 2 2
N staging    
  0 44 (66.7) 36 (55.4) 80 (61.1)
  1 20 (30.3) 27 (41.5) 47 (36.0)
  2 1 (1.5) 0 (0.0) 1 (0.8)
  X 1 (1.5) 2 (3.1) 3 (2.3)
M staging    
  0 65 (98.5) 65 (100) 130 (99.2)
  X 1 (1.5) 0 (0) 1 (0.8)
  Data lacking 0   
Estrogen receptor status    
  Negative 2 (3.0) 2 (3.1) 4 (3.1)
  Positive 64 (97.0) 63 (96.9) 127 (96.9)
Progesterone receptor status    
  Negative 7 (10.6) 6 (9.2) 13 (9.9)
  Positive 59 (89.4) 59 (90.8) 118 (90.1)
ECOG performance status    
  0 42 (63.6) 38 (58.5) 80 (61.1)
  1 20 (30.3) 24 (36.9) 44 (33.6)
  2 4 (6.1) 3 (4.6) 7 (5.3)
  3 0 (0) 0 (0.0) 0 (0)
  1. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; LET, letrozole alone; LET + ZOL, letrozole plus zoledronic acid; SD, standard deviation.